Role of RAS/BRAF and PIK3CA mutations in tissue and plasma for prognostic assessment in metastatic colorectal cancer (mCRC).

First-line durvalumab with arterial chemotherapy in major portal invaded hepatocellular carcinoma: The phase 2 DurHope study with biomolecular analyses. This is an ASCO Meeting Abstract from the 2025 ...